Genzyme crunches consent-decree fine numbers; SAFC expands for dry powder media;

> Genzyme says it anticipates a $175-million penalty in the forthcoming FDA consent decree for its Boston area manufacturing plant, in addition to percentage-of-revenue fines for any operations-corrections deadlines it misses going forward. Genzyme release

> Sigma-Aldrich company SAFC is spending $6.15 million to expand its Lenexa, KS, facility for the upstream and downstream production of dry powder media and reagents. SAFC release

> Former FDA commissioner Andrew von Eschenbach has joined the scientific advisory board of nanotechnology company Arrowhead Research. Arrowhead release

> The Chao Center for Industrial Pharmacy and Contract Manufacturing at Purdue Research Park is closing its doors. Item

> Kimberly-Clark Professional has introduced the Kimtech Pure G3 and G5 sterling nitrile cleanroom gloves. Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.